LAUSR

Objective To assess the diagnostic value of predictive models based on synthetic magnetic resonance imaging (syMRI), multiplexed sensitivity encoding (MUSE) sequences, and Breast Imaging Reporting and Data System (BI-RADS) in the differentiation of benign and malignant breast lesions. Methods Clinical and MRI data of 158 patients with breast lesions who underwent dynamic contrast-enhanced MRI (DCE-MRI), syMRI, and MUSE sequences between September 2019 and December 2020 were retrospectively collected. The apparent diffusion coefficient (ADC) values of MUSE and quantitative relaxation parameters (longitudinal and transverse relaxation times [T1, T2], and proton density [PD] values) of syMRI were measured, and the parameter variation values and change in their ratios were calculated. The patients were randomly divided into training (n = 111) and validation (n = 47) groups at a ratio of 7:3. A nomogram was built based on univariate and multivariate logistic regression analyses in the training group and was verified in the validation group. The discriminatory and predictive capacities of the nomogram were assessed by the receiver operating characteristic curve and area under the curve (AUC). The AUC was compared by DeLong test. Results In the training group, univariate analysis showed that age, lesion diameter, menopausal status, ADC, T2pre, PDpre, PDGd, T2Delta, and T2ratio were significantly different between benign and malignant breast lesions (P < 0.05). Multivariate logistic regression analysis showed that ADC and T2pre were significant variables (all P < 0.05) in breast cancer diagnosis. The quantitative model (model A: ADC, T2pre), BI-RADS model (model B), and multi-parameter model (model C: ADC, T2pre, BI-RADS) were established by combining the above independent variables, among which model C had the highest diagnostic performance, with AUC of 0.965 and 0.986 in the training and validation groups, respectively. Conclusions The prediction model established based on syMRI, MUSE sequence, and BI-RADS is helpful for clinical differentiation of breast tumors and provides more accurate information for individualized diagnosis.